Factor VIIa (Recombinant) For Acquired Hemophilia
Coagulation factor VIIa (recombinant) (NovoSeven, Novo Nordisk) is the first recombinant therapy to be approved for the treatment of bleeding episodes and for the prevention of bleeding in patients with acquired hemophilia who are undergoing invasive surgical procedures.
First introduced in 1999, NovoSeven is currently indicated for the treatment of bleeding episodes in hemophilia A or B patients with inhibitors to factor VIII or factor IX and for bleeding episodes in patients with congenital factor VII deficiency. It is also indicated for prevention of bleeding in surgical interventions or invasive procedures in these patients.
skelaxin metaxalone
Functionally indistinguishable from naturally occurring activated factor VII, NovoSeven is produced in baby hamster kidney cells that have been genetically engineered to express recombinant factor VII. This agent is not derived from plasma, and it poses no risk of human viral transmission through its use.
